Navigate US Food and Drug Administration requirements for Pakistani pharmaceutical exporters.
Abbreviated New Drug Application for generic drug approvals
US-FDA pre-approval inspection of manufacturing facilities
Current Good Manufacturing Practice regulations (21 CFR Part 211)
ANDA review: 12–24 months under GDUFA II framework
Pakistani pharmaceutical manufacturers wishing to export to the United States must register their facilities with the US-FDA through the Drug Establishment Registration system. Facility registration is renewable annually between October 1 and December 31. All facilities must comply with 21 CFR Part 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals).
Generic drug manufacturers must file an Abbreviated New Drug Application (ANDA) with the US-FDA's Office of Generic Drugs (OGD). The ANDA must demonstrate bioequivalence to the reference listed drug (RLD) and include comprehensive chemistry, manufacturing, and controls (CMC) data. Under GDUFA II commitments, standard ANDA review is targeted within 10 months.
Pakistani manufacturers often receive Complete Response Letters (CRLs) related to data integrity concerns, inadequate validation data, or GMP deficiencies identified during pre-approval inspections (PAIs). Working with experienced US regulatory consultants and implementing robust quality management systems (QMS) before submitting ANDAs is strongly recommended.